Kornimate/medical-research-clean huggingface dataset:
septic cardiac deficiency and meningococcal severe sepsis

Conditions: Meningococcal Infections; Septic Shock; Severe Sepsis

Summary: use of brain natriuretic peptide to evaluate the cardiac function in the course of meningococcal septic shock or severe sepsis.

objectives: determining sensibility and specificity of bnp blood level to detect myocardial dysfunction in septic shock or severe sepsis due to neisseria meningitidis in children. methods: prospective multicentric clinical trial including 7 french pediatric intensive care units. serial cardiac ultra sounds and blood sampling will be done for patients hospitalized for purpura fulminans beginning at the time of admission in pediatric intensive care. any child from 6 months to 18 years without preexisting cardiac disease and presenting with purpura fulminans will be enrolled after obtaining consent of both parents. from adult's studies on septic shock and bnp, a total number of 30 patients was calculated to be necessary to prove the interest of bnp in this indication.

Eligibility criteria:
inclusion criteria: * children * 6 months to 18 years aged * without previous cardiac pathology * hospitalized in the participating pediatric intensive care units for serious sepsis with extensive purpura exclusion criteria: * heart malformative disorder with right-left shunt * pre-existent known cardiac insufficiency whatever is the origin * concomitant participation in another trial * patient in period of exclusion from another trial * not membership in a national insurance scheme

Keywords: brain natriuretic peptide cardiac function meningococcal infections septic shock severe sepsis
treatment of bacterial vaginosis in early pregnancy in skaraborg and the effect on spontaneous preterm delivery

Conditions: Bacterial Vaginosis

Summary: bacterial vaginosis (bv) is a known risk factor for preterm delivery. this study was conducted in an attempt to investigate if treatment of bacterial vaginosis in early pregnancy could reduce the risk for preterm delivery. women were screened for bacterial vaginosis during the first visits at the maternal health care unit with a vaginal sample that were taken by the midwife or by herself. after the vaginal samples was air dried it was sent to the gynaecological department and was investigated using hay/ison classification. eligible women were those who had lived in skaraborg and delivered at skaraborg hospital.

the study has started 2007 and will continue until 2014. pregnant women that will come to the maternal health care units in gestational week 8-11 will be offered to be screened for bacterial vaginosis. a vaginal sample will be taken by the midwife or by the women herself. the vaginal sample is air-dried and sent to the gynecological. there it is investigated using hay/ison classification for the diagnosis of bacterial vaginosis. women with bacterial vaginosis will be offered treatment with topical clindamycin treatment for 7 days if the women has passed the 12th gestational week. a control sample for the test of cure will be done after 10 week. if not cured of bv she will be offered a new treatment. all women will be followed until delivery.

Eligibility criteria:
inclusion criteria: * pregnant women screened for bacterial vaginosis in early pregnancy exclusion criteria: * women not delivered at skaraborg hospital.
efficacy of re-challenge with immune-checkpoints inhibitors in advanced non-small-cell lung cancer patients: a retrospective observational study

Conditions: Non Small Cell Lung Cancer

Summary: this is a multicentre, retrospective, national observational study aiming to describe clinical outcomes of advanced nsclc patients that performed an icp re-challenge during their history of disease. the objective of this study is to evaluate the icp re-challenge efficacy.

immune checkpoint inhibitors (icp), including nivolumab, pembrolizumab and atezolizumab, are currently approved by ema (european medicines agency) and ansm (national agency for the safety of medicines and health products) for the treatment of advanced non-small-cell lung cancer (nsclc) in first or second line with different strategies according to the expression of pd-l1. moreover, durvalumab recently entered the treatment strategy for locally advanced disease in pd-l1 expressing (\>1%) patients. median progression-free survival (pfs) for patients with advanced nsclc is approximately 3 to 4 months with this kind of drugs and chemotherapy is currently the reference treatment after progression. however, the scientific community is now evaluating the re-challenge strategy. notably, in patients with metastatic melanoma, different trials have shown the efficacy and the good safety of re-challenge with ipilimumab or a combination of nivolumab and ipilimumab after an initial period of disease control with ipilimumab. to date, no studies have reported the clinical benefit of icp re-challenge in patients with advanced nsclc. the effectiveness and tolerance of the re-challenge strategy with the same or another icp remains therefore a major issue.

Eligibility criteria:
inclusion criteria: * diagnosis of nsclc * advanced disease (stage iii-iv) according to the tnm 7th /8th edition classification at the beginning of first icp * patients must have received at least two lines of icp during their history of disease * patients with egfr mutation and/or alk translocation must have received all specific target agents regularly reimbursed (during the reporting period) prior to the first pci exclusion criteria: • opposition form signed by the living patient or opposition clearly indicated in the deceased patient's medical records
hämeenlinna metabolic syndrome research program: oxidized ldl and arterial elasticity in metabolic syndrome and controls (hms-01)

Conditions: Metabolic Syndrome

Summary: mechanisms that link metabolic syndrome to atherosclerosis are incompletely understood. as a part of hämeenlinna metabolic syndrome research program (hms), 40 men with metabolic syndrome and their 40 physically active controls (age: 30 to 65 years) are compared in a cross-sectional study. except routine laboratory parameters, arterial elasticity and levels of oxidized ldl are determined. study hypothesis: levels of oxidized ldl and findings in arterial elasticity may differ between subjects with metabolic syndrome and controls explaining the elevated risk for cardiovascular diseases among patients with metabolic syndrome.

accumulation of oxidized low-density lipoproteins in the intimae of arteries together with risk factors known to enhance atherosclerosis, damage the endothelium of the arterial wall. dysfunction of the endothelium leads into loss of elasticity of the artery. especially a reduction in the elasticity of small arteries has been found prominent in atherosclerosis and is believed to serve as a marker for early stages of atherosclerosis. in this study, we investigate whether the levels of oxidized ldl and arterial elasticity differ between patients with metabolic syndrome and their physically active controls. oxidized ldl is assessed by a two-site elisa immunoassay (mercodia, uppsala, sweden). the capacitive elasticity of large arteries (c1) and the reflective elasticity of small arteries (c2) are automatically assessed by the cr-2000 as a mean of five most similar pulse waves appearing during the measurement. c1 identifies the elastic properties of aorta and other large arteries, c2 the endothelial function of the microvascular circulation. proper statistical methods are used to reveal possible differences and their significance between the patients and controls.

Eligibility criteria:
inclusion criteria: group 1: metabolic syndrome * 40 finnish men with metabolic syndrome (mets) defined according to national cholesterol education program (ncep) adult treatment panel iii * mets diagnosed in routine health examination and laboratory tests * age: 30 to 65 years group 2: control * 40 age-matched men * exercise physically more than three times a week and more than 30 minutes per exercise on regular basis * never been studied or treated because of cardiovascular disease exclusion criteria: * cholesterol-lowering medication * ace-inhibitor medication * angiotensin-receptor blocker medication

Keywords: metabolic syndrome oxidized low density lipoprotein arterial elasticity diabetes mellitus cardiovascular diseases
pk pd study of ida and azithromycin for ntds ( combontds )

Conditions: Lymphatic Filariasis; Yaws; Trauma

Summary: this is a pharmacokinetic and pharmacodynamic study evaluating the safety of co-administering azithromycin alongside the new ida (ivermectin, diethylcarbamazine, albendazole) combination treatment for lf. individuals will be randomised to receive azithromycin alone, ida or combination therapy. clinical and biochemical monitoring for safety will be undertaken. drug levels will be measured in each of the three arms to assess whether combination therapy significantly alters drug levels.


Eligibility criteria:
inclusion criteria: * adult aged 18-65 * able to give informed consent exclusion criteria: * known chronic illness * hb \<7 at baseline * liver function or creatinine \* 1.5 upper limit of normal * urinary tract infection at baseline * pregnancy (female participants only) * routine medications which interact with study drugs * lactose/gluten intolerance * permanent disability impeding study participation
effects of balance exercises with and without clamshell exercises after menopause

Conditions: Menopause

Summary: exercise-based balance intervention is structured program of physical exercises intended to enhance balance, stability, and clamshell exercises are known as an exercise-based balance intervention. a crucial component of physical therapy and fitness regimens targeted at enhancing stability, reducing the risk of falls, and promoting general physical health is exercise-based balance therapies. women's ability to function both physically and mentally can be significantly impacted by menopause. to find out the effects of an exercise based balance intervention on physical and clamshell exercises after menopause certain consequences can be lessened by address these alterations with focused interventions.these will be a randomized clinical trial and will be conducted in bhawalpur victoria hospital and mehran rehab clinic. this study will be completed in the time duration of 10 months after the approval of synopsis. non probability convenience sampling technique will be used and participants will be recruited in study after the randomization.80 participants with age between 50-65 years will be included in the study according to the inclusion criteria. group a will receive balance exercises and clamshell exercises group b will be recieve only balance exercises the tool that will be used are the sit and raised test , y balance test, romberg test for check the balance. timed raised chair task for check the strength . timed up and go for check the mobility . heel shin touch test for check the coordination. time shuttle runs for check the speed. step test for check the power after data collection, data will be analyzed by using sppss 26.


Eligibility criteria:
inclusion criteria: * age 65 years or older; * having significant concerns about their balance * participants to be living independently in the community * berg's balance scale scores more than 41/56 indicating minimal fall risk were included in the study exclusion criteria: * participants were excluded from the study if their vision was compromised so that they were unable to see objects on the floor or recognize the instructor's movements * progressive neurologic disease which could impair balance * hypertensive * unable to understand, speak, or hear

Keywords: balance clamshell postmenupause
efficacy of omega-3 fatty acid therapy in preventing gastrointestinal bleeding in patients with cf-lvad

Conditions: Heart Failure; Gastrointestinal Bleeding

Summary: this study evaluates the efficacy of high-dose fish oil in decreasing rates of gastrointestinal bleeding in patients with continuous-flow left ventricular assist devices. half of the patients without history of bleeding will receive fish oil while the other half will not. half of the patients with history of bleeding will receive fish oil while the other half will not. markers of angiogenesis and inflammation, as well as changes in the microbiome will be assessed in each group.

a potential mechanism of bleeding in patients with continuous-flow left ventricular assist devices (cf-lvad) is dysfunctional angiogenesis. angiogenesis is a complicated process controlled by several markers. previous studies have shown that elevated angiopoietin-2 and tnf-alpha are associated with bleeding events in cf-lvad patients. fish oil has anti-inflammatory and potentially anti-angiogenic properties. a retrospective study of cf-lvad patients on high-dose fish oil showed a marked decrease in gastrointestinal bleeding rates in these patients. additionally, these patients had lower levels of circulating angiopoietin-2. fish oil is known to have an effect on the microbiome, and the aforementioned effects may be seen in changes of the microbiota.

Eligibility criteria:
inclusion criteria: 1. subject has signed consent 2. age \> 18 years 3. subjects with a cf-lvad or are scheduled to receive a cf-lvad implant exclusion criteria: 1. psychiatric disorder or disease, irreversible cognitive dysfunction or psychosocial issues that might impair compliance with the study. 2. patients already taking fish oil.

Keywords: angiogenesis inflammation microbiome
impact of incomplete endometrial ablation

Conditions: Heavy Menstrual Bleeding

Summary: the aim of the proposed protocol is to study the impact of incomplete endometrial ablation on the pbac score, reintervention, satisfaction, controlled bleeding and dysmenorrhea at 24 months after novasure endometrial ablation, in women with heavy menstrual bleeding treated at máxima medical centre veldhoven, in the netherlands.

the primary outcome is blood loss at 24 months after treatment, measured with the pbac-score according to higham. to calculate this score women were asked, in the mira and mira2 study, to record their menstrual blood loss for one month counting the number of super tampons or pads used each day. the total score was calculated using a score of 1 for each lightly saturated tampons. for pads the scores were respectively 1, 5 and 20. secondary outcome measures were controlled bleeding, defined as a pbac-score not exceeding 75 points, pbac score of zero, re-intervention rate 24 months after treatment, satisfaction with treatment (measured with a 5-point likert scale) and dysmenorrhea. in addition, multiple variables were analyzed in predicting the occurrence of incomplete endometrial ablation, including age, bmi, cavum length, cavum width, ablation time, ablation power, nulliparity, sterilization in history, section caesarea in history, position of the uterus (avf/rvf), presence of myomas, the presence of adenomyosis and surgery under local anesthesia, generally without sterilization or generally in combination with sterilization. information was collected from epd and the mira and mira2 databases.

Eligibility criteria:
inclusion criteria: * endometrial ablation between 2012 and 2023 in máxima medical centre * women had to suffer from heavy menstrual bleeding exclusion criteria: - no saved hysteroscopy images or bad quality hysteroscopy images
fundal block in pre-menopausal women to reduce pain during outpatient-based endometrial ablation (fundal-pain)

Conditions: Pain

Summary: the objective of this study is to assess the efficacy of a fundal block in reducing women's perception of pain during novasure endometrial ablation (ea) in an outpatient-based setting.

the researchers aim to determine whether participants receiving the paracervical and fundal block (experimental group) achieve clinically and statistically significant reductions in self-reported pain during novasure ea, as compared to those receiving paracervical block (control group). all women will obtain concurrent procedural sedation. women's perception of pain will be recorded on a scale from 0 to 10 using the visual analogue scale (vas). the researchers hypothesize that the participants receiving combined paracervical and fundal block will experience less pain during the active procedure, as compared to those receiving paracervical block alone.

Eligibility criteria:
inclusion criteria: * abnormal uterine bleeding * pre-menopausal as determined by the presence of menstrual cycles * must have completed their family or have no desire to preserve fertility * uterus and cervix must meet eligibility criteria; based on hysteroscopy exam performed by the physician prior to the ablation procedure * must be a female participant 25-55 years of age exclusion criteria: * any uterine characteristics that preclude performing ea * past allergic reactions to local anaesthetic * weight \<50kg * submucous fibroids requiring myomectomy * lack of patient consent

Keywords: abnormal uterine bleeding endometrial ablation novasure pain
nsaids vs opioids for post-op pain in supracondylar humerus fractures

Conditions: Supracondylar Humerus Fracture

Summary: the purpose of this study is to determine if using the combination of acetaminophen (also known as tylenol) and ibuprofen (also known as motrin or advil) will provide equal or better pain control as compared to acetaminophen-hydrocodone (also known as lortab), in children with broken elbows who need surgery. this study will examine whether the combination of acetaminophen and ibuprofen can provide pain control as well as or better than acetaminophen-hydrocodone so that doctors might be able to prescribe less acetaminophen-hydrocodone (which can be addictive) to children in the future. currently, the standard of care for pain control following this kind of elbow surgery is acetaminophen-hydrocodone.

for this study, participants will be randomized (randomly assigned) to either receive scheduled acetaminophen-hydrocodone (which is the current standard of care treatment) or acetaminophen and ibuprofen (the experimental treatment) for post operative pain control following surgery for supracondylar humerus fracture. patients in the experimental treatment group who require 2 doses of breakthrough pain medication in a row in order to control their pain will be switched to the standard of care treatment. follow up information regarding outcomes post-discharge will be collected via secure email or text 48-72 hours post-discharge.

Eligibility criteria:
inclusion criteria: * isolated supracondylar humerus fracture * undergoing closed reduction with percutaneous pinning (crpp) exclusion criteria: * allergies to acetaminophen, ibuprofen, and/or acetaminophen-hydrocodone * liver or renal disease * history of bleeding disorder * medical diagnosis of juvenile arthritis * on chronic nsaids or opioids prior to the procedure * medical diagnosis of coagulopathies, open fractures, other injuries at time of diagnosis (multi-system trauma) * vascular compromise and/or compartment syndrome upon admission

Keywords: elbow surgery pain
phase 1 weekly dosing of sch 727965 in patients with advanced cancer (study p04629am6)

Conditions: Solid Tumors; Lymphoma, Non-Hodgkin; Multiple Myeloma; Leukemia, Lymphocytic, Chronic. B-Cell

Summary: the study will evaluate the safety, tolerability, maximum administered dose, and dose limiting toxicity of sch 727965 administered as an intravenous infusion on days 1, 8 and 15 of each 28 day cycle in participants with solid tumors, non hodgkins lymphoma, multiple myeloma or chronic lymphocytic leukemia.


Eligibility criteria:
inclusion criteria: * age \>=18 years, either sex, any race. * eastern cooperative oncology group performance status of 0, 1, or 2. * there must be no known standard therapy, or disease must be refractory to standard therapy * adequate hematologic, renal, and hepatic organ function and laboratory parameters * for advanced solid tumors, non-hodgkin's lymphoma, or multiple myeloma: * participants must have histologically proven solid tumors, non-hodgkin's lymphoma, or multiple myeloma. * evaluable malignancy must be present by computed tomography or magnetic resonance imaging, obtained within 4 weeks prior to the start of treatment with sch 727965. * subjects with multiple myeloma must have measurable disease defined as: * serum monoclonal protein greater than 0.5 g/dl or urine light chain excretion of greater than 0.2 g/24-hour obtained within 4 weeks prior to the start of treatment. * participants with lower m protein values or nonsecretory myeloma are eligible if measurable disease can be established within 4 weeks prior to start of treatment, such as: * serum free light chain ratio greater than 5 times the normal ratio limit; and/or * measurable soft tissue plasmacytoma greater than 2 cm, by either physical examination and/or applicable radiographs; and/or * bone marrow involvement greater than 30%. * for b-cell chronic lymphocytic leukemia (b-cll): * diagnosis of b-cll according to the national cancer institute working group (nci-wg) criteria or a histological diagnosis of small lymphocytic lymphoma. * disease must be evaluable according to nci-wg response criteria. exclusion criteria: * symptomatic brain metastases or primary central nervous system malignancy. * previous radiation therapy to \>25% of the total bone marrow. * previous treatment with sch 727965. * known hiv infection.